GRPR and Familial prostate cancer: Our study demonstrates the successful design of potent GRPR radioantagonists featuring non-linear, conformationally restricted structures, and holds strong potential to significantly expand the range of diagnostic and therapeutic radioligands available for PET imaging of prostate cancer.